Velikyan, I.; Grinnemo, K.-H.; Flodin, V.; James, S.; Thelander, U.; Wagner, M.; Rodin, S.; Kero, T.; Korsgren, O.; Eriksson, O.
Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction. Pharmaceuticals 2025, 18, 1833.
https://doi.org/10.3390/ph18121833
AMA Style
Velikyan I, Grinnemo K-H, Flodin V, James S, Thelander U, Wagner M, Rodin S, Kero T, Korsgren O, Eriksson O.
Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction. Pharmaceuticals. 2025; 18(12):1833.
https://doi.org/10.3390/ph18121833
Chicago/Turabian Style
Velikyan, Irina, Karl-Henrik Grinnemo, Viktor Flodin, Stefan James, Ulrika Thelander, Michael Wagner, Sergey Rodin, Tanja Kero, Olle Korsgren, and Olof Eriksson.
2025. "Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction" Pharmaceuticals 18, no. 12: 1833.
https://doi.org/10.3390/ph18121833
APA Style
Velikyan, I., Grinnemo, K.-H., Flodin, V., James, S., Thelander, U., Wagner, M., Rodin, S., Kero, T., Korsgren, O., & Eriksson, O.
(2025). Ga-68-Labeled Affibody Molecule-Based Radiopharmaceutical Targeting Platelet Derived Growth Factor Receptor Beta for Detection of Active Fibrosis in Patients with Myocardial Infarction. Pharmaceuticals, 18(12), 1833.
https://doi.org/10.3390/ph18121833
